Animal models in the study of hepatitis C virus-associated liver pathologies

Expert Review of Gastroenterology and Hepatology

Volumn 5, Issue 3, 2011, Pages 341-352

  Lerat, Hervé ^a   Higgs, Martin ^a   Pawlotsky, Jean Michel ^a  

^a UNIVERSITÉ PARIS EST CRÉTEIL   (France)

Author keywords

animal models; hepatitis C virus; hepatocellular carcinoma; liver pathology; steatosis; transgenic mice

Indexed keywords

APOLIPOPROTEIN B; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45 BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; LIPID TRANSFER PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; REACTIVE OXYGEN METABOLITE; RETINOID X RECEPTOR; STAT1 PROTEIN; STAT3 PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; SUPPRESSOR OF CYTOKINE SIGNALING 1; TRIACYLGLYCEROL; TRIACYLGLYCEROL TRANSFER PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN; VIRUS PROTEIN;

APOPTOSIS; CAUSAL ATTRIBUTION; DISEASE COURSE; DNA DAMAGE; DNA REPAIR; DNA REPLICATION; DNA SYNTHESIS; DOUBLE STRANDED DNA BREAK; FATTY LIVER; GENOMIC INSTABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; LIPID METABOLISM; LIPOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; NONALCOHOLIC FATTY LIVER; NONHUMAN; PATHOGENESIS; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RISK FACTOR; VIRUS ENTRY; VIRUS GENOME; VIRUS REPLICATION;

ANIMALS; APOPTOSIS; DISEASE MODELS, ANIMAL; FATTY LIVER; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INSULIN RESISTANCE; LIPID METABOLISM; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; METABOLIC SYNDROME X; MICE; MICE, TRANSGENIC; SPECIES SPECIFICITY;

EID: 79958268921     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/egh.11.14     Document Type: Review

References (121)

1. Imperial JC. Natural history of chronic hepatitis B and C. J. Gastroenterol. Hepatol. 14(Suppl.), S1-S5 (1999). (Pubitemid 29281857)
2. Thomas H, Lemon S, Zuckerman AJ. Viral Hepatitis. Blackwell Publishing Ltd, Oxford, UK (2005).
3. Knipe D, Howley P, Griffin D, et al. Fields Virology. Lippincott Williams & Wilkins, PA, USA (2007).
4. Castello G, Scala S, Palmieri G, Curley SA, Izzo F. HCV-related hepatocellular carcinoma: from chronic inflammation to cancer. Clin. Immunol. 134(3), 237-250 (2010).
5. Bartenschlager R, Sparacio S. Hepatitis C virus molecular clones and their replication capacity in vivo and in cell culture. Virus Res. 127(2), 195-207 (2007). (Pubitemid 47058197)
6. Lindenbach BD, Evans MJ, Syder AJ, et al. Complete replication of hepatitis C virus in cell culture. Science 309(5734), 623-626 (2005). (Pubitemid 41033648)
7. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285(5424), 110-113 (1999). (Pubitemid 29307577)
8. Wakita T, Pietschmann T, Kato T et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11(7), 791-796 (2005). (Pubitemid 41021213)
9. Zhong J, Gastaminza P, Cheng G, et al. Robust hepatitis C virus infection in vitro. Proc. Natl Acad. Sci. USA 102(26), 9294-9299 (2005). (Pubitemid 40923557)
10. Bukh J. A critical role for the chimpanzee model in the study of hepatitis C. Hepatology 39(6), 1469-1475 (2004). (Pubitemid 38702645)
11. Muchmore EA. Chimpanzee models for human disease and immunobiology. Immunol. Rev. 183, 86-93 (2001). (Pubitemid 34015440)
12. Xie ZC, Riezu-Boj JI, Lasarte JJ, et al. Transmission of hepatitis C virus infection to tree shrews. Virology 244(2), 513-520 (1998).
13. Abe K, Kurata T, Teramoto Y, Shiga J, Shikata T. Lack of susceptibility of various primates and woodchucks to hepatitis C virus. J. Med. Primatol. 22(7-8), 433-434 (1993).
14. Garson JA, Whitby K, Watkins P, Morgan AJ. Lack of susceptibility of the cottontop tamarin to hepatitis C infection. J. Med. Virol. 52(3), 286-288 (1997). (Pubitemid 27305748)
15. Sithebe NP, Kew MC, Mphahlele MJ, et al. Lack of susceptibility of Chacma baboons (Papio ursinus orientalis) to hepatitis C virus infection. J. Med. Virol. 66(4), 468-471 (2002). (Pubitemid 34203234)
16. Takikawa S, Engle RE, Faulk KN, Emerson SU, Purcell RH, Bukh J. Molecular evolution of GB virus B hepatitis virus during acute resolving and persistent infections in experimentally infected tamarins. J. Gen. Virol. 91(Pt 3), 727-733 (2010).
17. Galun E, Burakova T, Ketzinel M, et al. Hepatitis C virus viremia in SCID-BNX mouse chimera. J. Infect. Dis. 172(1), 25-30 (1995).
18. Ilan E, Arazi J, Nussbaum O, et al. The hepatitis C virus (HCV)-Trimera mouse: a model for evaluation of agents against HCV. J. Infect. Dis. 185(2), 153-161 (2002). (Pubitemid 34056438)
19. Wu GY, Konishi M, Walton CM, Olive D, Hayashi K, Wu CH. A novel immunocompetent rat model of HCV infection and hepatitis. Gastroenterology 128(5), 1416-1423 (2005). (Pubitemid 40712190)
20. Heckel JL, Sandgren EP, Degen JL, Palmiter RD, Brinster RL. Neonatal bleeding in transgenic mice expressing urokinase-type plasminogen activator. Cell 62(3), 447-456 (1990).
21. Sandgren EP, Palmiter RD, Heckel JL, Daugherty CC, Brinster RL, Degen JL. Complete hepatic regeneration after somatic deletion of an albumin-plasminogen activator transgene. Cell 66(2), 245-256 (1991). (Pubitemid 121001363)
22. Rhim JA, Sandgren EP, Degen JL, Palmiter RD, Brinster RL. Replacement of diseased mouse liver by hepatic cell transplantation. Science 263(5150), 1149-1152 (1994). (Pubitemid 24105963)
23. Dandri M, Burda MR, Torok E, et al. Repopulation of mouse liver with human hepatocytes and in vivo infection with hepatitis B virus. Hepatology 33(4), 981-988 (2001). (Pubitemid 32246649)
24. Lootens L, Meuleman P, Pozo OJ, Van Eenoo P, Leroux-Roels G, Delbeke FT. uPA+/+-SCID mouse with humanized liver as a model for in vivo metabolism of exogenous steroids: methandienone as a case study. Clin. Chem. 55(10), 1783-1793 (2009).
25. Meuleman P, Libbrecht L, De Vos R et al. Morphological and biochemical characterization of a human liver in a uPA-SCID mouse chimera. Hepatology 41(4), 847-856 (2005). (Pubitemid 40462948)
26. Tsuge M, Hiraga N, Takaishi H, et al. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus. Hepatology 42(5), 1046-1054 (2005). (Pubitemid 43112671)
27. Morosan S, Hez-Deroubaix S, Lunel F et al. Liver-stage development of Plasmodium falciparum, in a humanized mouse model. J. Infect. Dis. 193(7), 996-1004 (2006).
28. Mercer DF, Schiller DE, Elliott JF, et al. Hepatitis C virus replication in mice with chimeric human livers. Nat. Med. 7(8), 927-933 (2001). (Pubitemid 32756430)
29. Turrini P, Sasso R, Germoni S, et al. Development of humanized mice for the study of hepatitis C virus infection. Transplant. Proc. 38(4), 1181-1184 (2006). (Pubitemid 43815893)
30. Lindenbach BD, Meuleman P, Ploss A, et al. Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc. Natl Acad. Sci. USA 103(10), 3805-3809 (2006). (Pubitemid 43376636)
31. Meuleman P, Leroux-Roels G. The human liver-uPA-SCID mouse: a model for the evaluation of antiviral compounds against HBV and HCV. Antiviral Res. 80(3), 231-238 (2008).
32. Vanwolleghem T, Libbrecht L, Hansen BE et al. Factors determining successful engraftment of hepatocytes and susceptibility to hepatitis B and C virus infection in uPA-SCID mice. J. Hepatol. 53(3), 468-476 (2010).
33. Robinet E, Baumert TF. Host and viral determinants for engraftment of virus permissive human hepatocytes into chimeric immunodeficient mice. J. Hepatol. 53(3), 421-423 (2010).
34. Suemizu H, Hasegawa M, Kawai K, et al. Establishment of a humanized model of liver using NOD/Shi-SCID IL2RGnull mice. Biochem. Biophys. Res. Commun. 377(1), 248-252 (2008).
35. Song X, Guo Y, Duo S, et al. A mouse model of inducible liver injury caused by tet-on regulated urokinase for studies of hepatocyte transplantation. Am. J. Pathol. 175(5), 1975-1983 (2009).
36. Weglarz TC, Degen JL, Sandgren EP. Hepatocyte transplantation into diseased mouse liver. Kinetics of parenchymal repopulation and identification of the proliferative capacity of tetraploid and octaploid hepatocytes. Am. J. Pathol. 157(6), 1963-1974 (2000).
37. Grompe M, Lindstedt S, al-Dhalimy M et al. Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type I. Nat. Genet. 10(4), 453-460 (1995).
38. Azuma H, Paulk N, Ranade A, et al. Robust expansion of human hepatocytes in FAH-/-/RAG2-/-/Il2RG-/- mice. Nat. Biotech. 25(8), 903-910 (2007). (Pubitemid 47236918)
39. Bissig KD, Le TT, Woods NB, Verma IM. Repopulation of adult and neonatal mice with human hepatocytes: a chimeric animal model. Proc. Natl Acad. Sci. USA 104(51), 20507-20511 (2007).
40. Bissig KD, Wieland SF, Tran P, et al. Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment. J. Clin. Invest. 120(3), 924-930 (2010).
41. Washburn M, Bility M, Zhang L, et al. A humanized mouse model to study hepatitis C virus infection, immune response and liver disease. Gastroenterology 140, 1334-1344 (2011).
42. Kneteman NM, Weiner AJ, OConnell J et al. Anti-HCV therapies in chimeric SCID-Alb/uPA mice parallel outcomes in human clinical application. Hepatology 43(6), 1346-1353 (2006). (Pubitemid 43980114)
43. Vanwolleghem T, Meuleman P, Libbrecht L, Roskams T, De Vos R, Leroux-Roels G. Ultra-rapid cardiotoxicity of the hepatitis C virus protease inhibitor BILN 2061 in the urokinase-type plasminogen activator mouse. Gastroenterology 133(4), 1144-1155 (2007). (Pubitemid 47494454)
44. Joyce MA, Walters KA, Lamb SE, et al. HCV induces oxidative and ER stress, and sensitizes infected cells to apoptosis in SCID/Alb-uPA mice. PLoS pathogens 5(2), e1000291 (2009).
45. Legrand N, Ploss A, Balling R, et al. Humanized mice for modeling human infectious disease: challenges, progress, and outlook. Cell Host Microbe 6(1), 5-9 (2009).
46. McCaffrey AP, Ohashi K, Meuse L, et al. Determinants of hepatitis C translational initiation in vitro, in cultured cells and mice. Mol. Ther. 5(6), 676-684 (2002). (Pubitemid 34619060)
47. Gordon JW, Ruddle FH. Integration and stable germ line transmission of genes injected into mouse pronuclei. Science 214(4526), 1244-1246 (1981). (Pubitemid 12167330)
48. Cruise MW, Melief HM, Lukens J, Soguero C, Hahn YS. Increased Fas ligand expression of CD4+ T cells by HCV core induces T cell-dependent hepatic inflammation. J. Leukoc. Biol. 78(2), 412-425 (2005). (Pubitemid 41061313)
49. Honda A, Hatano M, Kohara M et al. HCV-core protein accelerates recovery from the insensitivity of liver cells to Fas-mediated apoptosis induced by an injection of anti-Fas antibody in mice. J. Hepatol. 33(3), 440-447 (2000). (Pubitemid 30663382)
50. Ishikawa T, Shibuya K, Yasui K, Mitamura K, Ueda S. Expression of hepatitis C virus core protein associated with malignant lymphoma in transgenic mice. Comp. Immunol. Microbiol. Infect. Dis. 26(2), 115-124 (2003). (Pubitemid 36221448)
51. Kamegaya Y, Hiasa Y, Zukerberg L, et al. Hepatitis C virus acts as a tumor accelerator by blocking apoptosis in a mouse model of hepatocarcinogenesis. Hepatology 41(3), 660-667 (2005). (Pubitemid 40289515)
52. Kato T, Miyamoto M, Date T, et al. Repeated hepatocyte injury promotes hepatic tumorigenesis in hepatitis C virus transgenic mice. Cancer Sci. 94(8), 679-685 (2003). (Pubitemid 37160924)
53. Moriya K, Yotsuyanagi H, Shintani Y, et al. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J. Gen. Virol. 78(Pt 7), 1527-1531 (1997). (Pubitemid 27343089)
54. Pasquinelli C, Shoenberger JM, Chung J et al. Hepatitis C virus core and E2 protein expression in transgenic mice. Hepatology 25(3), 719-727 (1997). (Pubitemid 27106460)
55. Soguero C, Joo M, Chianese-Bullock KA, Nguyen DT, Tung K, Hahn YS. Hepatitis C virus core protein leads to immune suppression and liver damage in a transgenic murine model. J. Virol. 76(18), 9345-9354 (2002). (Pubitemid 34919892)
56. Wang AG, Moon HB, Lee YH, et al. Transgenic expression of Korean type hepatitis C virus core protein and related mutants in mice. Exp. Mol. Med. 36(6), 588-593 (2004).
57. Koike K, Moriya K, Ishibashi K, et al. Expression of hepatitis C virus envelope proteins in transgenic mice. J. Gen. Virol. 76(Pt 12), 3031-3038 (1995). (Pubitemid 26003112)
58. Honda A, Arai Y, Hirota N, et al. Hepatitis C virus structural proteins induce liver cell injury in transgenic mice. J. Med. Virol. 59(3), 281-289 (1999). (Pubitemid 29468067)
59. Kawamura T, Furusaka A, Koziel MJ, et al. Transgenic expression of hepatitis C virus structural proteins in the mouse. Hepatology 25(4), 1014-1021 (1997). (Pubitemid 27157150)
60. Korenaga M, Wang T, Li Y, et al. Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production. J. Biol. Chem. 280(45), 37481-37488 (2005). (Pubitemid 41642356)
61. Lerat H, Honda M, Beard MR, et al. Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. Gastroenterology 122(2), 352-365 (2002). (Pubitemid 34116987)
62. Naas T, Ghorbani M, Alvarez-Maya I, et al. Characterization of liver histopathology in a transgenic mouse model expressing genotype 1a hepatitis C virus core and envelope proteins 1 and 2. J. Gen. Virol. 86(Pt 8), 2185-2196 (2005). (Pubitemid 41057523)
63. Wakita T, Taya C, Katsume A, et al. Efficient conditional transgene expression in hepatitis C virus cDNA transgenic mice mediated by the Cre/loxP system. J. Biol. Chem. 273(15), 9001-9006 (1998). (Pubitemid 28176187)
64. Frelin L, Brenndorfer ED, Ahlen G, et al. The hepatitis C virus and immune evasion: non-structural 3/4A transgenic mice are resistant to lethal tumour necrosis factor a mediated liver disease. Gut 55(10), 1475-1483 (2006). (Pubitemid 44476794)
65. Majumder M, Ghosh AK, Steele R, et al. Hepatitis C virus NS5A protein impairs TNF-mediated hepatic apoptosis, but not by an anti-FAS antibody, in transgenic mice. Virology 294(1), 94-105 (2002). (Pubitemid 34921293)
66. Alonzi T, Agrati C, Costabile B, et al. Steatosis and intrahepatic lymphocyte recruitment in hepatitis C virus transgenic mice. J. Gen. Virol. 85(Pt 6), 1509-1520 (2004). (Pubitemid 38807748)
67. Blindenbacher A, Duong FH, Hunziker L et al. Expression of hepatitis c virus proteins inhibits interferon a signaling in the liver of transgenic mice. Gastroenterology 124(5), 1465-1475 (2003). (Pubitemid 36531819)
68. Uprichard SL, Chung J, Chisari FV, Wakita T. Replication of a hepatitis C virus replicon clone in mouse cells. Virol. J. 3, 89 (2006).
69. Klotman PE, Notkins AL. Transgenic models of human immunodeficiency virus type-1. Curr. Top. Microbiol. Immunol. 206, 197-222 (1996). (Pubitemid 26024634)
70. Racaniello VR, Ren R. Transgenic mice and the pathogenesis of poliomyelitis. Arch. Virol. 9, 79-86 (1994).
71. Masciopinto F, Freer G, Burgio VL, et al. Expression of human CD81 in transgenic mice does not confer susceptibility to hepatitis C virus infection. Virology 304(2), 187-196 (2002). (Pubitemid 36069162)
72. Ploss A, Evans MJ, Gaysinskaya VA et al. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 457(7231), 882-886 (2009).
73. Dorner M. A genetically humanized, immunocompetent mouse model for hepatitis C virus infection. Presented at: 17th International Meeting on Hepatitis C Virus and Related Viruses. Yokohama, Japan, 10-14 September 2010.
74. Ploss A, Rice CM. Towards a small animal model for hepatitis C. EMBO Rep. 10(11), 1220-1227 (2009).
75. Bitzegeio J, Bankwitz D, Hueging K et al. Adaptation of hepatitis C virus to mouse CD81 permits infection of mouse cells in the absence of human entry factors. PLoS Pathogens 6(7), e1000978 (2010).
76. Moriya K, Fujie H, Shintani Y, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat. Med. 4(9), 1065-1067 (1998). (Pubitemid 28417341)
77. Moriya K, Todoroki T, Tsutsumi T, et al. Increase in the concentration of carbon monounsaturated fatty acids in the liver with hepatitis C: analysis in transgenic mice and humans. Biochem. Biophys. Res. Commun. 281(5), 1207-1212 (2001). (Pubitemid 32924547)
78. Lerat H, Kammoun HL, Hainault I, et al. Hepatitis C virus proteins induce lipogenesis and defective triglyceride secretion in transgenic mice. J. Biol. Chem. 284(48), 33466-33474 (2009).
79. Perlemuter G, Sabile A, Letteron P, et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J. 16(2), 185-194 (2002). (Pubitemid 34113012)
80. Dai CY, Chuang WL, Ho CK, et al. Associations between hepatitis C viremia and low serum triglyceride and cholesterol levels: a community-based study. J. Hepatol. 49(1), 9-16 (2008).
81. Mirandola S, Realdon S, Iqbal J, et al. Liver microsomal triglyceride transfer protein is involved in hepatitis C liver steatosis. Gastroenterology 130(6), 1661-1669 (2006). (Pubitemid 43668848)
82. Moriishi K, Mochizuki R, Moriya K, et al. Critical role of PA28g in hepatitis C virus-associated steatogenesis and hepatocarcinogenesis. Proc. Natl Acad. Sci. USA 104(5), 1661-1666 (2007). (Pubitemid 46214647)
83. Kim KH, Hong SP, Kim K, Park MJ, Kim KJ, Cheong J. HCV core protein induces hepatic lipid accumulation by activating SREBP1 and PPARg. Biochem. Biophys. Res. Commun. 355(4), 883-888 (2007). (Pubitemid 46366910)
84. Waris G, Felmlee DJ, Negro F, Siddiqui A. Hepatitis C virus induces proteolytic cleavage of sterol regulatory element binding proteins and stimulates their phosphorylation via oxidative stress. J. Virol. 81(15), 8122-8130 (2007). (Pubitemid 47101498)
85. Su AI, Pezacki JP, Wodicka L, et al. Genomic analysis of the host response to hepatitis C virus infection. Proc. Natl Acad. Sci. USA 99(24), 15669-15674 (2002). (Pubitemid 35403989)
86. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev. 20(5), 649-688 (1999). (Pubitemid 30650602)
87. Tanaka N, Moriya K, Kiyosawa K, Koike K, Aoyama T. Hepatitis C virus core protein induces spontaneous and persistent activation of peroxisome proliferatoractivated receptor a in transgenic mice: implications for HCV-associated hepatocarcinogenesis. Int. J. Cancer 122(1), 124-131 (2008). (Pubitemid 350209986)
88. Tanaka N, Moriya K, Kiyosawa K, Koike K, Gonzalez FJ, Aoyama T. PPARa activation is essential for HCV core protein-induced hepatic steatosis and hepatocellular carcinoma in mice. J. Clin. Invest. 118(2), 683-694 (2008). (Pubitemid 351206557)
89. Barbaro G, Di Lorenzo G, Asti A, et al. Hepatocellular mitochondrial alterations in patients with chronic hepatitis C: ultrastructural and biochemical findings. Am. J. Gastroenterol. 94(8), 2198-2205 (1999). (Pubitemid 29374554)
90. Horiike S, Kawanishi S, Kaito M, et al. Accumulation of 8-nitroguanine in the liver of patients with chronic hepatitis C. J. Hepatol. 43(3), 403-410 (2005). (Pubitemid 41111420)
91. Valgimigli M, Valgimigli L, Trere D, et al. Oxidative stress EPR measurement in human liver by radical-probe technique. Correlation with etiology, histology and cell proliferation. Free Radic. Res. 36(9), 939-948 (2002). (Pubitemid 34863641)
92. Dharancy S, Malapel M, Perlemuter G et al. Impaired expression of the peroxisome proliferator-activated receptor a during hepatitis C virus infection. Gastroenterology 128(2), 334-342 (2005). (Pubitemid 40431087)
93. Miyamoto H, Moriishi K, Moriya K, et al. Involvement of the PA28g-dependent pathway in insulin resistance induced by hepatitis C virus core protein. J. Virol. 81(4), 1727-1735 (2007). (Pubitemid 46214447)
94. Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 126(3), 840-848 (2004). (Pubitemid 38298332)
95. Kawaguchi T, Yoshida T, Harada M, et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am. J. Pathol. 165(5), 1499-1508 (2004). (Pubitemid 39435150)
96. Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. Dig. Liver Dis. 42(Suppl. 3), S206-S214 (2010).
97. El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 36(5 Suppl. 1), S74-S83 (2002). (Pubitemid 35253466)
98. Saito I, Miyamura T, Ohbayashi A, et al. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc. Natl Acad. Sci. USA 87(17), 6547-6549 (1990).
99. Simonetti RG, Camma C, Fiorello F, et al. Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis. A case-control study. Ann. Intern. Med. 116(2), 97-102 (1992).
100. Klopstock N, Katzenellenbogen M, Pappo O, et al. HCV tumor promoting effect is dependent on host genetic background. PloS One 4(4), e5025 (2009).
101. Koike K. Pathogenesis of HCV-associated HCC: dual-pass carcinogenesis through activation of oxidative stress and intracellular signaling. Hepatol. Res. 37(Suppl. 2), S115-S120 (2007).
102. Halliwell B, Aruoma OI. DNA damage by oxygen-derived species. Its mechanism and measurement in mammalian systems. FEBS Lett. 281(1-2), 9-19 (1991).
103. Machida K, Cheng KT, Lai CK, Jeng KS, Sung VM, Lai MM. Hepatitis C virus triggers mitochondrial permeability transition with production of reactive oxygen species, leading to DNA damage and STAT3 activation. J. Virol. 80(14), 7199-7207 (2006). (Pubitemid 44025216)
104. Machida K, Cheng KT, Sung VM, Lee KJ, Levine AM, Lai MM. Hepatitis C virus infection activates the immunologic (type II) isoform of nitric oxide synthase and thereby enhances DNA damage and mutations of cellular genes. J. Virol. 78(16), 8835-8843 (2004). (Pubitemid 39025148)
105. Machida K, Tsukamoto H, Liu JC, et al. c-Jun mediates hepatitis C virus hepatocarcinogenesis through signal transducer and activator of transcription 3 and nitric oxide-dependent impairment of oxidative DNA repair. Hepatology 52(2), 480-492 (2010).
106. Furutani T, Hino K, Okuda M, et al. Hepatic iron overload induces hepatocellular carcinoma in transgenic mice expressing the hepatitis C virus polyprotein. Gastroenterology 130(7), 2087-2098 (2006). (Pubitemid 43816966)
107. Kato J, Kobune M, Nakamura T, et al. Normalization of elevated hepatic 8-hydroxy-2-deoxyguanosine levels in chronic hepatitis C patients by phlebotomy and low iron diet. Cancer Res. 61(24), 8697-8702 (2001). (Pubitemid 34013879)
108. Negrini S, Gorgoulis VG, Halazonetis TD. Genomic instability - an evolving hallmark of cancer. Nat. Rev. 11(3), 220-228 (2010).
109. Miyoshi H, Fujie H, Shintani Y, et al. Hepatitis C virus core protein exerts an inhibitory effect on suppressor of cytokine signaling (SOCS)-1 gene expression. J. Hepatol. 43(5), 757-763 (2005). (Pubitemid 41414500)
110. Higgs MR, Lerat H, Pawlotsky JM. Downregulation of Gadd45b expression by hepatitis C virus leads to defective cell cycle arrest. Cancer Res. 70(12), 4901-4911 (2010).
111. Tsutsumi T, Suzuki T, Moriya K, et al. Alteration of intrahepatic cytokine expression and AP-1 activation in transgenic mice expressing hepatitis C virus core protein. Virology 304(2), 415-424 (2002). (Pubitemid 36069179)
112. Tsutsumi T, Suzuki T, Moriya K, et al. Hepatitis C virus core protein activates ERK and p38 MAPK in cooperation with ethanol in transgenic mice. Hepatology 38(4), 820-828 (2003). (Pubitemid 37221665)
113. Di Micco R, Fumagalli M, Cicalese A, et al. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 444(7119), 638-642 (2006). (Pubitemid 44864443)
114. Gorgoulis VG, Vassiliou LV, Karakaidos P et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434(7035), 907-913 (2005). (Pubitemid 40559004)
115. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature 432(7015), 316-323 (2004). (Pubitemid 39551659)
116. McGivern DR, Lemon SM. Tumor suppressors, chromosomal instability, and hepatitis C virus-associated liver cancer. Annu. Rev. Pathol. 4, 399-415 (2009).
117. Disson O, Haouzi D, Desagher S, et al. Impaired clearance of virus-infected hepatocytes in transgenic mice expressing the hepatitis C virus polyprotein. Gastroenterology 126(3), 859-872 (2004). (Pubitemid 38298334)
118. Simonin Y, Disson O, Lerat H, et al. Calpain activation by hepatitis C virus proteins inhibits the extrinsic apoptotic signaling pathway. Hepatology 50(5), 1370-1379 (2009).
119. Erdtmann L, Franck N, Lerat H, et al. The hepatitis C virus NS2 protein is an inhibitor of CIDE-B-induced apoptosis. J. Biol. Chem. 278(20), 18256-18264 (2003). (Pubitemid 36799444)
120. El-Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch. Intern. Med. 160(21), 3227-3230 (2000).
121. Keasler VV, Lerat H, Madden CR, et al. Increased liver pathology in hepatitis C virus transgenic mice expressing the hepatitis B virus X protein. Virology 347(2), 466-475 (2006).